Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
“We estimate that around 18,000 New Zealanders with chronic heart failure will benefit in the first year of funding empagliflozin, rising to over 37,000 people per year after five years of funding.